A Survival Study for Women With Advanced Lung Cancer Who Have Not Previously Received Chemotherapy.
Status:
Terminated
Trial end date:
2006-12-01
Target enrollment:
Participant gender:
Summary
This is a randomized, open-label, multinational, phase III study in women with
histologically- or cytologically-confirmed advanced NSCLC who are chemotherapy naïve and have
PS 2. Study drug will be administered on day 1 of each 21 day cycle